SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with community chatter focused on a potential breakout and significant price movement. Bullish sentiment is fueled by expectations of strong earnings and guidance, and some are pointing to potential tailwinds like future rate cuts and crypto integration. The stock's ability to break through the $30 resistance level is a key point of discussion.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amidst discussions about its new NFL partnership and an analyst report questioning the move, sparking debate about the company's direction. The community is also analyzing recent price action, pondering whether the stock is undervalued or if deeper issues are at play, while closely watching for potential catalysts.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as the company recently launched new AI chips aimed at competing with Nvidia and AMD in the data center market, generating significant buzz and a surge in stock price. Community discussions revolve around the potential impact of these chips, revenue projections, and whether Qualcomm can truly challenge the dominance of existing players. Some analysts express skepticism, citing the chips' specifications and disclosed customer base, while others highlight the company's shift towards AI infrastructure.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors weigh the potential impact of a new web browser from OpenAI, a possible competitor to Google Chrome. Despite the concerns, many community members view the dip as a buying opportunity, emphasizing Google's diverse portfolio and strong position in AI and cloud computing.  Additionally, some analysts have recently raised their price targets for the stock, citing positive advertising and cloud channel checks.

Trump For President

Trump Crypto is trending amid mixed community sentiment, with some users discussing potential pumps and scams while others express political opinions related to Trump. Bullish investors are anticipating gains, while bearish investors are pointing to the coin's performance since launch. The coin seems to be moving in response to triggers related to its namesake figure.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors react to the company's plans to cut up to 30,000 corporate jobs, with community members discussing the implications for the broader economy and the potential impact of AI and automation on the workforce. Some view the layoffs as a cost-cutting measure before earnings, while others speculate about a potential recession. Despite the concerns, some investors see the dip as a buying opportunity, drawing comparisons to past layoff announcements that preceded stock rallies.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a significant volume spike and discussions around its potential for a parabolic move. Community members are closely watching for continuation and a possible short squeeze, citing a very low float and insider ownership. Some traders are also pointing to a recent revenue growth update as a potential catalyst.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending due to a sharp decline following the pause of its Phase 3 trials for nex-z after a patient experienced liver problems, leading to a significant stock drop. The community is debating whether this is an overreaction and a buying opportunity, or a justified re-pricing due to potential issues with its leading program. Technical analysis suggests a potential rebound around the $15 support level, while some analysts remain optimistic about risk-mitigation strategies.

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Campbell, CA.

Semler Scientific Inc

Semler Scientific is trending following news of its acquisition by Strive in an all-stock deal, which represents a significant premium for SMLR shareholders. The community is actively discussing the implications of the merger, particularly the fixed exchange ratio and potential arbitrage opportunities, with some expressing concerns about dilution. Bullish sentiment centers around the combined company's increased Bitcoin holdings and potential for a short squeeze.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending amid discussions of a potential short squeeze and excitement around the company's role in the AI revolution, particularly its fiber network and recent partnership. Community members are pointing to institutional ownership and insider buying as bullish signals, with some speculating about upcoming announcements and positive earnings. Overall, the conversation is centered on the company's AI-driven growth potential and its undervaluation in the market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Sangamo (SGMO) a New Buy Stock

Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

Stock Index Futures Slip as Tariff-Driven Selloff Continues, U.S. Jobs Report and Powell Speech in Focus

June S&P 500 E-Mini futures (ESM25) are down -0.84%, and June Nasdaq 100 E-Mini futures (NQM25) are down -0.52% this morning, pointing to a continued selloff on Wall Street following U.S. President Donald Trump’s announcement of sweeping tariffs, while investors await the key U.S. payrolls report and remarks from Federal Reserve Chair Jerome Powell.

Shares of Eli Lilly &amp; Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by fears of a global economic fallout from President Donald Trump’s reciprocal tariff blitz.However, retail investors took heart in the fact that the pharmaceutical industry suffered a relatively lighter blow compared to sectors like technology and manufacturing, as it was largely spared from the government’s targeted tariff list.On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’<figure class="image"><img style="aspect-ratio:1314/320;" src="https://news.stocktwits-cdn.com/LLY_sentiment_and_message_volume_on_April_3_png_0331ef626f.webp" alt="LLY sentiment and message volume on April 3.png" width="1314" height="320"><figcaption>LLY sentiment and message volume on April 3. | source: Stocktwits</figcaption></figure>“LLY isn’t even affected. Loading up on calls at the open!” one user posted early Thursday when the stock was still in the green.<stembedurl>https://stocktwits.com/DayTrader6969/message/610222644</stembedurl>Another user pointed out that Trump had specifically highlighted Lilly as a company investing in U.S. infrastructure and job creation, suggesting it could ultimately benefit from the administration’s policies.<stembedurl>https://stocktwits.com/MrChoudhury/message/610228354</stembedurl>Back in February, when Trump threatened to impose tariffs on drug imports, Lilly unveiled a plan to invest $27 billion on new plants in the United States over the next five years.However, as drugmakers dig through the fine print of Trump's sweeping executive order — which imposes a 10% baseline duty on most imports — uncertainty remains over whether the pharmaceutical industry will be completely spared.Media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/pharma-stocks-up-on-us-tariff-exemptions-but-analyst-flags-a-46b-import-cost-risk-3964936">reports</a> suggest a U.S. official hinted that a separate round of tariffs targeting pharmaceuticals is still on the table.According to Bernstein analysts, if country-specific tariffs are applied, the pharmaceutical industry could face up to $46 billion in additional import costs.For now, investors seem to be taking a small win in stride.Retail traders on Thursday also zeroed in on Lilly’s newly inked licensing deal with Sangamo Therapeutics for its adeno-associated virus capsid,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sgmo-stock-falls-after-q4-2024-earnings-miss/ch7KGZ9Rbca">STAC-BBB</a>, designed to improve the delivery of IV-administered genomic medicines for neurological diseases.The deal grants Lilly exclusive global rights to use STAC-BBB for one initial central nervous system target, with the option to expand to four more for additional fees.Lilly's stock has gained a little over 1% this year, while the Dow Jones U.S. Health Care Index is up over 2.5% and the S&amp;P 500 Health Care Index has risen over 4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption

On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’ 

Equity

Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following disappointing quarterly earnings, but retail investors held their bullish ground.Sangamo reported a fourth-quarter adjusted loss per share of $0.11, narrowing significantly from a loss of $0.34 a year earlier. However, this was worse than Wall Street's expected $0.09 per share loss.Revenue of $7.6 million also fell short of the consensus estimate of $11.7 million.&nbsp;CEO Sandy Macrae emphasized the company's progress over the past year, notably securing FDA approval for clinical trials of ST-503, a potential treatment for idiopathic small fiber neuropathy (iSFN)."We believe our neurology pipeline represents important potential value. In addition, we continue to engage in Fabry business development negotiations, in an effort to capitalize the business for the future," he said.Macrae added that 2025 will be a pivotal year, with plans to begin patient enrollment and dosing for the iSFN clinical study by midyear.&nbsp;The company also aims to submit a Biologics License Application (BLA) for its Fabry disease program in the second half of the year.On Stocktwits, sentiment for Sangamo ended Monday on an 'extremely bullish' note, with message volume exploding by 1200% from a day earlier.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SGMO_sentiment_and_message_volume_as_of_March_17_png_2c103aadf6.webp" alt="SGMO sentiment and message volume as of March 17.png" width="1316" height="302"><figcaption>SGMO sentiment and message volume as of March 17. | source: Stocktwits</figcaption></figure>Several optimistic users expressed confidence in Macrae's remarks about securing a third potential agreement with a major pharmaceutical company for its adeno-associated virus (AAV) capsid, STAC-BBB. The technology is designed to enhance the delivery of intravenously administered genomic medicines for specific neurological conditions.Sangamo has already licensed STAC-BBB to Roche's Genentech and Astellas Pharma.<stembedurl>https://stocktwits.com/BurkeTheBizarre15/message/608344985</stembedurl><stembedurl>https://stocktwits.com/Who_is_JohnnyGalt/message/608344869</stembedurl>Sangamo has been under pressure since December, when Pfizer ended a hemophilia drug development partnership, citing slow patient uptake for such therapies.Shares of the company have shed only about 1% this year but are up 20% over the past 12 months.According to Koyfin, five out of eight analysts covering the stock rate it 'buy' or 'strong buy', while the rest recommend 'hold'.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Sangamo Therapeutics Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.626
Prev Close	$0.6333
Open	$0.6488
Dividend Yield	0.00%
50-Day Moving Average	$0.5997
Beta	1.64
Avg. Volume	5.53M
PE Ratio	-2.23

52-Week High	$3.18
52-Week Low	$0.4111
Market Capitalization	$191.07M
EPS (Annual)	-$0.4856
Price to Book	8.81
Revenue Per Employee	$315,846.99
Enterprise Value/EBITDA	N/A

SGMO
Sangamo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMO News

SGMOSangamo Therapeutics Inc